{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:10:39Z","timestamp":1720789839927},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The worldwide incidence of melanoma has risen rapidly in the past 50 years and is a considerable public health burden in the United States, with significant financial implications. Studies have demonstrated the potential anticarcinogenic effects of antihypertensive agents, specifically beta-blockers, in patients with prostate cancer, breast cancer, and lately cutaneous malignant melanoma. This article explores the empirical clinical evidence of propranolol's anticarcinogenic effects on melanoma and the chemoprotective mechanisms of beta-blockers and other agents that have been used to modify melanoma progression.<\/jats:p>","DOI":"10.1097\/01.jaa.0000558241.84003.91","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T19:57:18Z","timestamp":1570564638000},"page":"1-5","source":"Crossref","is-referenced-by-count":3,"title":["Can propranolol prevent progression of melanoma?"],"prefix":"10.1097","volume":"32","author":[{"given":"Jason","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"6","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3322\/caac.21352","article-title":"State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now","volume":"66","author":"Tripp","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"R2-20230817","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737140.2018.1421460","article-title":"How to use neoadjuvant medical treatment to maximize surgery in melanoma","volume":"18","author":"Amaral","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"R4-20230817","doi-asserted-by":"crossref","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch1","article-title":"Epidemiology of melanoma","author":"Matthews","year":"2017","journal-title":"Cutaneous Melanoma: Etiology and Therapy"},{"issue":"6","key":"R5-20230817","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","article-title":"Antihypertensive drug use and the risk of prostate cancer (Canada)","volume":"15","author":"Perron","year":"2004","journal-title":"Cancer Causes Control"},{"issue":"7","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"628","DOI":"10.18632\/oncotarget.197","article-title":"Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival","volume":"1","author":"Powe","year":"2010","journal-title":"Oncotarget"},{"issue":"11","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of b-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archinternmed.2011.131","article-title":"Treatment with b-blockers and reduced disease progression in patients with thick melanoma","volume":"171","author":"De Giorgi","year":"2011","journal-title":"Arch Intern Med"},{"issue":"2","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"e172908","DOI":"10.1001\/jamaoncol.2017.2908","article-title":"Propranolol for off-label treatment of patients with melanoma: results from a cohort study","volume":"4","author":"De Giorgi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"R10-20230817","first-page":"11","article-title":"b-blockers: a new and emerging treatment for melanoma","volume":"103","author":"De Giorgi","year":"2012","journal-title":"Recenti Prog Med"},{"issue":"23","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/jnci\/dji401","article-title":"Chronic stress and susceptibility to skin cancer","volume":"97","author":"Saul","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"4201","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1126\/science.168638","article-title":"Mouse mammary tumors: alteration of incidence as apparent function of stress","volume":"189","author":"Riley","year":"1975","journal-title":"Science"},{"issue":"12","key":"R13-20230817","first-page":"4514","article-title":"Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines","volume":"9","author":"Lutgendorf","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1078-0432.CCR-05-1698","article-title":"Stress hormone-mediated invasion of ovarian cancer cells","volume":"12","author":"Sood","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"R15-20230817","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4161\/cc.6.4.3829","article-title":"The neuroendocrine impact of chronic stress on cancer","volume":"6","author":"Thaker","year":"2007","journal-title":"Cell Cycle"},{"issue":"1","key":"R16-20230817","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"R17-20230817","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/01.RES.0000191541.06788.bb","article-title":"Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system","volume":"97","author":"Iaccarino","year":"2005","journal-title":"Circ Res"},{"issue":"9","key":"R18-20230817","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"R19-20230817","first-page":"177","article-title":"Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies","volume":"3","author":"Tawara","year":"2011","journal-title":"Cancer Manag Res"},{"issue":"2","key":"R20-20230817","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbi.2008.10.005","article-title":"Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression","volume":"23","author":"Yang","year":"2009","journal-title":"Brain Behav Immun"},{"issue":"3","key":"R21-20230817","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/labinvest.2012.175","article-title":"b-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines","volume":"93","author":"Moretti","year":"2013","journal-title":"Lab Invest"},{"issue":"4","key":"R22-20230817","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2007.06633.x","article-title":"A historical perspective on the development of b-adrenergic blockers","volume":"9","author":"Frishman","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"R23-20230817","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","article-title":"b-Adrenergic blockers","volume":"13","author":"Frishman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"R26-20230817","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/CMR.0000000000000317","article-title":"b-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up","volume":"27","author":"De Giorgi","year":"2017","journal-title":"Melanoma Res"},{"issue":"10","key":"R27-20230817","doi-asserted-by":"crossref","first-page":"797","DOI":"10.18632\/oncotarget.343","article-title":"Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment","volume":"2","author":"Pasquier","year":"2011","journal-title":"Oncotarget"},{"issue":"24","key":"R28-20230817","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"R29-20230817","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/phpp.12328","article-title":"Melanoma and nonmelanoma skin cancer chemoprevention: a role for nicotinamide","volume":"34","author":"Minocha","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"R30-20230817","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1684\/ejd.2017.3025","article-title":"Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study","volume":"27","author":"Drago","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"17","key":"R31-20230817","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"R32-20230817","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1751-1097.2010.00746.x","article-title":"Nicotinamide prevents ultraviolet radiation-induced cellular energy loss","volume":"86","author":"Park","year":"2010","journal-title":"Photochem Photobiol"},{"issue":"1","key":"R33-20230817","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/carcin\/bgn248","article-title":"Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans","volume":"30","author":"Yiasemides","year":"2009","journal-title":"Carcinogenesis"},{"issue":"2","key":"R34-20230817","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: an overview","volume":"5","author":"Chan","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"R35-20230817","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/aje\/kwq175","article-title":"Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk","volume":"172","author":"Salinas","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"R36-20230817","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000084818","article-title":"Association of regular aspirin use and breast cancer risk","volume":"68","author":"Swede","year":"2005","journal-title":"Oncology"},{"issue":"8","key":"R37-20230817","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cncr.27817","article-title":"Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative","volume":"119","author":"Gamba","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"R38-20230817","first-page":"303","article-title":"Expression of cyclooxygenase 2 in human malignant melanoma","volume":"61","author":"Denkert","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"R39-20230817","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/CMR.0b013e32834defec","article-title":"The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions","volume":"22","author":"Ku\u017abicki","year":"2012","journal-title":"Melanoma Res"},{"issue":"6","key":"R40-20230817","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1158\/1940-6207.CAPR-14-0018","article-title":"Aspirin and other NSAIDs as chemoprevention agents in melanoma","volume":"7","author":"Goodman","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5 suppl 1","key":"R41-20230817","first-page":"S17","article-title":"Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006","volume":"65","author":"Jemal","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"R42-20230817","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/21678707.2018.1512402","article-title":"Updates and challenges on treatment with BRAF\/MEK-inhibitors in melanoma","volume":"6","author":"Eroglu","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"issue":"7","key":"R43-20230817","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cam4.732","article-title":"Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials","volume":"5","author":"Yun","year":"2016","journal-title":"Cancer Med"},{"issue":"3","key":"R44-20230817","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4068\/cmj.2017.53.3.173","article-title":"Therapeutic Inhibitors against mutated BRAF and MEK for the treatment of metastatic melanoma","volume":"53","author":"Ryu","year":"2017","journal-title":"Chonnam Med J"},{"issue":"2","key":"R45-20230817","first-page":"96","article-title":"The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma","volume":"38","author":"McCain","year":"2013","journal-title":"P T"},{"issue":"11","key":"R46-20230817","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1586\/era.12.118","article-title":"b-adrenergic-blocking drugs and melanoma: current state of the art","volume":"12","author":"De Giorgi","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"R47-20230817","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/jid.2014.373","article-title":"Inhibition of human melanoma growth by a non-cardioselective b-blocker","volume":"135","author":"Wrobel","year":"2015","journal-title":"J Invest Dermatol"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01720610-201906000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:12:10Z","timestamp":1692321130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201906000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000558241.84003.91","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}